Please login to the form below

Not currently logged in
Email:
Password:

Cellectis

This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The latest from pharma, biotech and healthcare. Cellectis gains senior scientist from Novartis. ... on the development and long-term strategic planning for Cellectis’ innovative product portfolio,” said Dr.

Latest news

  • Sangamo bulks up in cell therapy with TxCell acquisition Sangamo bulks up in cell therapy with TxCell acquisition

    Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured TALENS.

  • Gilead signs $3bn-plus gene-editing deal with Sangamo Gilead signs $3bn-plus gene-editing deal with Sangamo

    The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    It may be that the FDA will exercise greater caution in Cellectis' case. ... UCART19 is partnered with Servier and Pfizer. Cellectis' Nasdaq-listed shares are currently trading at around $25, down from more than $32 ahead of the patient death announcement

  • Servier cleared to start US trials CAR-T therapy Servier cleared to start US trials CAR-T therapy

    The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’ CAR-T

  • Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

    Cellectis has been given the go-ahead by the FDA to start trials of its CAR-T immunotherapy UCART123 in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients however.

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Companies like Cellectis and partner Allogene are deploying TALEN to take a slightly different approach, using the gene-editing tool to create ‘off-the-shelf’ CAR-Ts that don’t require ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    Cell therapy company Cellectis remains an exponent of TALEN, while Bluebird is using a next- generation platform called MegaTals.

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Pharma deals in May 2015 Pharma deals in May 2015

    Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics